6533b856fe1ef96bd12b1e4e

RESEARCH PRODUCT

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment

Emanuela BoveriUmberto GianelliJürgen ThieleHans Michael KvasnickaFrancesco PassamontiVito FrancoAttilio OraziHeinz GisslingerTiziano BarbuiAyalew Tefferi

subject

WHO classificationPathologymedicine.medical_specialtyGroup trialPediatricsessential thrombocythemiaEssential thrombocythemiabusiness.industryMEDLINEmyelofibrosisHematologySettore MED/08 - Anatomia Patologicamedicine.diseaseWorld healthmedicine.anatomical_structuremedicineWHO classification; early primary myelofibrosis; essential thrombocythemiaearly primary myelofibrosiBone marrowMyelofibrosisWho classificationbusiness

description

Any study of myeloproliferative neoplasms (MPNs) that lacks adequate clinical input is doomed to cause diagnostic uncertainty and increased controversy. In the paper by Buhr et al. published in Haematologica,[1][1] the authors studied 102 cases of essential thrombocythemia (ET) and early primary

yearjournalcountryeditionlanguage
2012-03-01
10.3324/haematol.2011.061432http://hdl.handle.net/11383/2023290